142 related articles for article (PubMed ID: 12811843)
1. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma.
Furlan R; Bergami A; Cantarella D; Brambilla E; Taniguchi M; Dellabona P; Casorati G; Martino G
Eur J Immunol; 2003 Jul; 33(7):1830-8. PubMed ID: 12811843
[TBL] [Abstract][Full Text] [Related]
2. Combined nasal administration of encephalitogenic myelin basic protein peptide 68-86 and IL-10 suppressed incipient experimental allergic encephalomyelitis in Lewis rats.
Xu LY; Yang JS; Huang YM; Levi M; Link H; Xiao BG
Clin Immunol; 2000 Sep; 96(3):205-11. PubMed ID: 10964538
[TBL] [Abstract][Full Text] [Related]
3. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis.
Morini M; Roccatagliata L; Dell'Eva R; Pedemonte E; Furlan R; Minghelli S; Giunti D; Pfeffer U; Marchese M; Noonan D; Mancardi G; Albini A; Uccelli A
J Neuroimmunol; 2004 Mar; 148(1-2):146-53. PubMed ID: 14975595
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma regulates murine interferon-inducible T cell alpha chemokine (I-TAC) expression in dendritic cell lines and during experimental autoimmune encephalomyelitis (EAE).
Hamilton NH; Banyer JL; Hapel AJ; Mahalingam S; Ramsay AJ; Ramshaw IA; Thomson SA
Scand J Immunol; 2002 Feb; 55(2):171-7. PubMed ID: 11896933
[TBL] [Abstract][Full Text] [Related]
5. Invariant NKT cells producing IL-4 or IL-10, but not IFN-gamma, inhibit the Th1 response in experimental autoimmune encephalomyelitis, whereas none of these cells inhibits the Th17 response.
Oh SJ; Chung DH
J Immunol; 2011 Jun; 186(12):6815-21. PubMed ID: 21572032
[TBL] [Abstract][Full Text] [Related]
6. An MHC anchor-substituted analog of myelin oligodendrocyte glycoprotein 35-55 induces IFN-gamma and autoantibodies in the absence of experimental autoimmune encephalomyelitis and optic neuritis.
Ford ML; Evavold BD
Eur J Immunol; 2004 Feb; 34(2):388-97. PubMed ID: 14768043
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis.
Brod SA; Khan M
J Autoimmun; 1996 Feb; 9(1):11-20. PubMed ID: 8845048
[TBL] [Abstract][Full Text] [Related]
8. An interferon-gamma-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis.
Suryani S; Sutton I
J Neuroimmunol; 2007 Feb; 183(1-2):96-103. PubMed ID: 17240458
[TBL] [Abstract][Full Text] [Related]
9. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression.
Imler TJ; Petro TM
Int Immunopharmacol; 2009 Jan; 9(1):134-43. PubMed ID: 19022403
[TBL] [Abstract][Full Text] [Related]
10. Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis.
Bharhani MS; Chiu B; Na KS; Inman RD
Int Immunol; 2009 Jul; 21(7):859-70. PubMed ID: 19477915
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide.
Willenborg DO; Fordham SA; Staykova MA; Ramshaw IA; Cowden WB
J Immunol; 1999 Nov; 163(10):5278-86. PubMed ID: 10553050
[TBL] [Abstract][Full Text] [Related]
12. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
[TBL] [Abstract][Full Text] [Related]
13. Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies.
Montero E; Nussbaum G; Kaye JF; Perez R; Lage A; Ben-Nun A; Cohen IR
J Autoimmun; 2004 Aug; 23(1):1-7. PubMed ID: 15236747
[TBL] [Abstract][Full Text] [Related]
14. A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation.
Fu YF; Zhu YN; Ni J; Zhong XG; Tang W; Re YD; Shi LP; Wan J; Yang YF; Yuan C; Nan FJ; Lawson BR; Zuo JP
J Pharmacol Exp Ther; 2006 Nov; 319(2):799-808. PubMed ID: 16914558
[TBL] [Abstract][Full Text] [Related]
15. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide.
Tulley JM; Palmer JL; Gamelli RL; Faunce DE
Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934
[TBL] [Abstract][Full Text] [Related]
16. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
[TBL] [Abstract][Full Text] [Related]
17. A novel protective model against experimental allergic encephalomyelitis in mice expressing a transgenic TCR-specific for myelin oligodendrocyte glycoprotein.
Mendel I; Natarajan K; Ben-Nun A; Shevach EM
J Neuroimmunol; 2004 Apr; 149(1-2):10-21. PubMed ID: 15020060
[TBL] [Abstract][Full Text] [Related]
18. Soluble egg antigen from Schistosoma japonicum modulates the progression of chronic progressive experimental autoimmune encephalomyelitis via Th2-shift response.
Zheng X; Hu X; Zhou G; Lu Z; Qiu W; Bao J; Dai Y
J Neuroimmunol; 2008 Feb; 194(1-2):107-14. PubMed ID: 18207251
[TBL] [Abstract][Full Text] [Related]
19. CD62L is required for the priming of encephalitogenic T cells but does not play a major role in the effector phase of experimental autoimmune encephalomyelitis.
Li O; Liu JQ; Zhang H; Zheng P; Liu Y; Bai XF
Scand J Immunol; 2006 Aug; 64(2):117-24. PubMed ID: 16867156
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
Osada T; Morse MA; Lyerly HK; Clay TM
Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
